Deferred Tax Assets, Gross of Grace Therapeutics, Inc. from 31 Mar 2019 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
Summary
Grace Therapeutics, Inc. quarterly Deferred Tax Assets, Gross in USD history and change rate from 31 Mar 2019 to 31 Mar 2025.
  • Grace Therapeutics, Inc. Deferred Tax Assets, Gross for the quarter ending 31 Mar 2025 was $58,779,000, a 11% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Gross, Quarterly (USD)
Deferred Tax Assets, Gross, YoY Quarterly Change (%)

Grace Therapeutics, Inc. Quarterly Deferred Tax Assets, Gross (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $58,779,000 +$5,640,000 +11% 31 Mar 2025 10-K 23 Jun 2025 2025 FY
Q1 2024 $53,139,000 +$1,496,000 +2.9% 31 Mar 2024 10-K 23 Jun 2025 2025 FY
Q1 2023 $51,643,000 +$5,158,000 +11% 31 Mar 2023 10-K 23 Jun 2023 2023 FY
Q1 2022 $46,485,000 +$7,264,000 +19% 31 Mar 2022 10-K 23 Jun 2023 2023 FY
Q1 2021 $39,221,000 +$8,758,000 +29% 31 Mar 2021 10-K 22 Jun 2021 2021 FY
Q1 2020 $30,463,000 +$4,491,000 +17% 31 Mar 2020 10-K 22 Jun 2021 2021 FY
Q1 2019 $25,972,000 31 Mar 2019 10-K 29 Jun 2020 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.